𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies

✍ Scribed by Jonathan Davidson; Christer Allgulander; Mark H. Pollack; James Hartford; Janelle S. Erickson; James M. Russell; David Perahia; Madalaine M. Wohlreich; Janice Carlson; Joel Raskin


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
88 KB
Volume
23
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Objective

To assess the efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder (GAD).

Methods

Acute‐phase data from a subset of patients (≥65 years) with GAD were pooled from four randomized, double‐blind, placebo‐controlled trials of duloxetine (3 flexible, 1 fixed dosing). Patients were treated with duloxetine 60–120 mg once daily or placebo for 9–10 weeks. The primary outcome measure was the mean baseline‐to‐endpoint change in Hamilton anxiety scale (HAMA) total score. Secondary measures included the HAMA psychic and somatic anxiety subscales and the Hospital Anxiety Depression Scale (HADS).

Results

Of 1491 patients randomly assigned to treatment, 4.9% (duloxetine, n = 45; placebo, n = 28) were ≥ 65 years old. Compared with placebo‐treated patients, duloxetine‐treated patients experienced significantly greater improvements on the HAMA‐total (p = 0.029), the HAMA‐psychic anxiety factor (p = 0.034), HADS‐anxiety (p = 0.049) and ‐depression scales (p = 0.026), but not the HAMA somatic anxiety factor (p = 0.074). Nausea was reported significantly more often in duloxetine‐treated patients (30.0% vs. 7.1%, p = 0.023); duloxetine‐treated patients experienced greater weight loss (p = 0.018). More duloxetine‐treated patients discontinued treatment due to an adverse event (22.2% vs. 0%; p = 0.006).

Conclusion

Duloxetine was effective in an elderly patient subset with GAD, although there was a high rate of discontinuations due to adverse events. Copyright © 2008 John Wiley & Sons, Ltd.


📜 SIMILAR VOLUMES


Randomized, double-blind, placebo-contro
✍ M. Linden; D. Hadler; S. Hofmann 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

Generalized anxiety disorders are frequent, chronic, and disabling illnesses for which so far ideal drug treatment is not available. A new promising anxiolytic drug is DN-2327, a non-benzodiazepine isoindoline derivative, which has shown in animals to have anxiolytic, taming, antiaggressive, and ant

Efficacy of Venlafaxine ER in patients w
✍ Christer Allgulander; Richard Mangano; Jun Zhang; Alv A. Dahl; Ulla Lepola; Inge 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 1 views

## Abstract This study evaluated the anxiolytic efficacy, safety and tolerability of a flexible dose of venlafaxine extended release (ER) compared with placebo and paroxetine in the short‐term treatment of generalized social anxiety disorder (SAD). Adult outpatients with generalized SAD (__n__ = 43

Efficacy and tolerability of extended re
✍ Dan J. Stein; Borwin Bandelow; Charles Merideth; Bengt Olausson; Johan Szamosi; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 377 KB 👁 1 views

## Objective Prospectively planned pooled analysis evaluating efficacy and tolerability of acute quetiapine XR monotherapy in generalised anxiety disorder. ## Methods Data from three 10‐week, randomised, double‐blind, placebo‐controlled studies of similar design were analysed. ## Results At Wee

Efficacy of methotrexate treatment in pa
✍ Henrike van Dongen; Jill van Aken; Leroy R. Lard; Karen Visser; H. Karel Ronday; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

## Abstract ## Objective To determine whether patients with undifferentiated arthritis (UA; inflammatory, nontraumatic arthritis that cannot be diagnosed using current classification criteria) benefit from treatment with methotrexate (MTX). ## Methods The PRObable rheumatoid arthritis: Methotrex